AI Agents Replace Manual Pharma Workflows
AI agents and knowledge graphs are increasingly replacing manual workflows in life sciences, according to a new point of view from Axtria. The firm highlights use cases for commercial analytics in pharma and healthcare where intelligent agents can automate complex data gathering and analysis tasks previously handled by teams of specialists.
Knowledge graphs unify vast, siloed datasets, mapping relationships between entities like diseases, genes, and drugs to accelerate research. This structured approach allows AI agents to navigate complex biological networks, identify new drug targets, and even aid in biomarker discovery for diseases like Parkinson's. For commercial teams, this means AI can analyze market trends and predict which marketing tactics will be most effective for specific demographics. Axtria's InsightsMAx.ai platform, used by six of the top ten global pharma companies, exemplifies this shift with over 30 domain-specific autonomous agents. These "agentic AI" systems go beyond generating insights; they act independently to orchestrate workflows, such as automating steps in the forecasting process or flagging compliance issues in real-time. This move from isolated AI tools to an integrated, autonomous ecosystem is what enables scaling across the enterprise. The underlying architecture for these systems is also evolving, with 83% of pharmaceutical companies now using cloud services. Modern data stacks are shifting from centralized data lakes to more agile, decentralized "data mesh" architectures. This approach assigns data ownership to domain-specific teams, reducing bottlenecks and accelerating access to insights from weeks to hours. For analytics engineering, the rise of natural language to SQL (NL2SQL) capabilities is democratizing data access. Tools using models like Gemini and GPT-4 allow non-technical users to query databases in plain English, reducing the dependency on specialized data teams for routine analysis. This frees up engineers to focus on building more robust data platforms and governance frameworks. In this highly regulated environment, data observability is critical for building trust in AI-driven insights. Observability platforms provide end-to-end visibility into data pipelines, automatically detecting issues like schema changes or missing values before they impact downstream analytics. This proactive approach to data quality is essential for ensuring the reliability of systems that support both commercial decisions and patient care. This shift is creating a demand for Staff-plus engineers who can design and build these complex, distributed data systems. The role increasingly requires not just deep technical expertise in areas like microservices and cloud-native architecture, but also the ability to align technical decisions with business strategy. Companies are investing heavily, with the global commercial pharmaceutical analytics market projected to reach $18.49 billion by 2031.
